Big data analysis of outcomes in non-small cell lung cancer at a regional cancer institute with a coordinated precision medicine program. Interplatform and cross-cohort meta-analysis of tumor ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Lobular breast cancer patients gathered at Fred Hutch Cancer Center last week for a two-hour program featuring patient stories, epidemiological findings and new developments in screening and clinical ...

MSK created this program because we’re experts in treating this type of cancer. Lobular breast cancer is very different from invasive ductal carcinoma, the most common type of breast cancer. It’s ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?